Spirit acquires leading medical wearable technology developer Aseptika
Posted on October 10, 2016
Spirit INT (Leicester, UK), the parent company of refreshing British healthcare provider Spirit Healthcare (www.spirit-healthcare.co.uk), is further expanding its offer to patients and healthcare professionals through the acquisition of healthcare technology developer Aseptika, a pioneer in the medical wearable and self-care technology sectors.
Bringing Aseptika’s Activ8rlives (www.activ8rlives.com) range of self-monitoring solutions into the Spirit stable alongside its award-winning cloud-based technology CliniTouch Vie, the rapidly growing firm is on a mission to help all patients with long term conditions. From patients who have been recently diagnosed with respiratory problems to those with more complex needs such as Chronic Obstructive Pulmonary Disease (COPD) or Cystic Fibrosis, this extended portfolio will support patients as their healthcare requirements change over time.
Spirit’s CEO Chris Barker said: “At Spirit, we believe that we can offer patients greater control over their own health by rethinking the way that care is delivered and Aseptika shares this vision. The Aseptika team has exceptional experience developing pioneering technology and we’re looking to grow this capability at their Cambridgeshire hub. With these skills, Spirit will be able to accelerate its programme of innovation. We’re innovating and growing fast so we can empower more patients across the UK. This significant acquisition is the second that we’ve made and we’re certainly on the hunt for more acquisition opportunities in the near future.”
Aseptika founder Kevin Auton commented: “We are delighted to be joining the highly successful Spirit group of companies in delivering the new technologies, solutions and services needed to support the growing healthcare needs of the UK. Spirit exemplifies the drive and innovation of the SME sector in delivering the technologies and services our NHS will need in the coming months and years as it accelerates towards digital delivery of healthcare to make its finite resources go further.
“Both companies have been extensively supported through the Small Business Research Initiative for Healthcare (SBRI Healthcare) and Innovate UK programmes. We look forward to bringing the wearable medical monitor BuddyWOTCHTM and the patented home-use test to detect bacterial chest infections to the market to support patients with severe respiratory conditions. Spirit’s ability to build successful partnerships with NHS organisations are a vital route-to-market for the Activ8rlives brand alongside the clear synergies with the Clinitouch VieTM platform to support all levels of disease condition from simple consumer Apps to full telehealth monitoring with Spirits’ 24/7 customer and patient support centre. The benefits of this powerful combination are already evident.”
Barker added: “The Spirit and Aseptika teams have already been collaborating together to develop a cutting edge mobile technology to improve management of type 1 diabetes in a research project in Scotland as part of an SBRI competition so we are excited to explore the future potential of our partnership.”
Karen Livingstone, National Director of SBRI Healthcare and Director of Eastern Academic Health Science Network, commenting on the acquisition said: “I am particularly pleased to see that Aseptika – an SBRI Healthcare backed company – has found a British-based company to partner with. We know the health market place can be challenging for small companies so it is great that two have combined forces, with the UK economy benefiting from the growth in jobs and revenues.
Spirit Healthcare launched in 2009 and provides a range of products and services across several specialisms, including diabetes monitoring devices, structured diabetes education, ambulatory photodynamic therapy to treat non-melanoma skin cancers and cloud-based self-management of Chronic Obstructive Pulmonary Disease (COPD), heart failure and diabetes.
Aseptika began developing Activ8rlives in 2010 and is currently developing its third generation of integrated systems which can be used by consumers and their healthcare service providers using a wide range of platforms or devices to better enable effective and easy self-monitoring. Incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs), the systems currently focus on respiratory disease, promoting physical activity and weight management. Activ8rlives has 100,000 registered users and 5,000 device uploads to its Cloud database each day. Just like Spirit’s CliniTouch Vie (now certified as a Class 1 medical device), all data is held together in the UK and can be cross analysed in the Cloud to provide forecasts and learning for the user and clinician.
Aseptika’s Asthma+me solution announced as Winner of Best Patient-Focused Technological Development in 2019 Clinical & Research Excellence Awards
Posted on May 7, 2019
Self-care: Councils helping people look after themselves
Posted on March 11, 2019
Asthma: Young people in the UK 'more likely to die'
Posted on February 20, 2019
Young people are at higher risk of having an asthma attack than any other age group living with the condition, the charity Asthma UK is warning
Posted on January 23, 2019
Aseptika wins grant from Innovate UK to undertake a clinical trial with its child asthma solution
Posted on January 21, 2019